Bispecific antibodies for the management of relapsed/refractory multiple myeloma
Simple Summary Bispecific antibodies (BsAbs) provide a new mode of targeting multiple
myeloma (MM) plasma cells (PCs), basing their action on the activation and redirection of …
myeloma (MM) plasma cells (PCs), basing their action on the activation and redirection of …
New horizons in our understanding of precursor multiple myeloma and early interception
DM Cordas dos Santos, R Toenges, L Bertamini… - Nature Reviews …, 2024 - nature.com
Multiple myeloma is an incurable plasma cell malignancy that evolves over decades through
the selection and malignant transformation of monoclonal plasma cells. The evolution from …
the selection and malignant transformation of monoclonal plasma cells. The evolution from …
Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies
Teclistamab is a B-cell maturation antigen (BCMA)–directed bispecific antibody approved for
the treatment of patients with triple-class exposed relapsed/refractory multiple myeloma …
the treatment of patients with triple-class exposed relapsed/refractory multiple myeloma …
[HTML][HTML] Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel
Idecabtagene vicleucel (Ide-cel) has demonstrated excellent efficacy and durable responses
in patients with relapsed/refractory multiple myeloma (RRMM). However, the outcomes with …
in patients with relapsed/refractory multiple myeloma (RRMM). However, the outcomes with …
Real-world safety and Health care resource utilization of teclistamab under an outpatient model for step-up dosing administration
TB Sandahl, SA Soefje, R Fonseca… - JCO Oncology …, 2024 - ascopubs.org
PURPOSE Teclistamab is initiated with a step-up dosing (SUD) schedule to mitigate the risk
of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity …
of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity …
Mechanisms and salvage treatments in patients with multiple myeloma relapsed post-BCMA CAR-T cell therapy
B Fu, R Liu, G Gao, Z Lin, A He - Frontiers in Immunology, 2024 - frontiersin.org
Chimeric antigen receptor T-cell (CAR-T) therapy has ushered in a new era for the treatment
of multiple myeloma (MM). Numerous clinical studies, especially those involving B-cell …
of multiple myeloma (MM). Numerous clinical studies, especially those involving B-cell …
Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen …
The presence of extramedullary disease (EMD) has been associated with poor outcomes in
patients with relapsed-refractory multiple myeloma (RRMM). Herein, we report the outcomes …
patients with relapsed-refractory multiple myeloma (RRMM). Herein, we report the outcomes …
[HTML][HTML] Seamless Navigation of Bispecific Therapies: Optimizing Management and Outpatient Access With a Focus on Coordination
Bispecific antibodies (BsAbs) have emerged as crucial therapeutic agents for patients with
relapsed/refractory diffuse large B-cell lymphoma, multiple myeloma, and most recently, lung …
relapsed/refractory diffuse large B-cell lymphoma, multiple myeloma, and most recently, lung …
Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives
RD Parrondo, S Ailawadhi, C Cerchione - Frontiers in Oncology, 2024 - frontiersin.org
Patients with relapsed/refractory multiple myeloma (RRMM) that are refractory to the five
most active anti-MM drugs, so-called penta-refractory MM, have historically had dismal …
most active anti-MM drugs, so-called penta-refractory MM, have historically had dismal …
Charting the Course: Sequencing Immunotherapy for Multiple Myeloma
Multiple chimeric antigen receptor (CAR) T-cell and bispecific antibody (bsAb) therapies
have been approved, demonstrating impressive clinical efficacy in relapsed/refractory …
have been approved, demonstrating impressive clinical efficacy in relapsed/refractory …